eCite Digital Repository

Patterns of Presentation and Treatment Outcomes of Non-clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia

Citation

Naher, S and Padinharakam, S and Balakrishnar, B and Chua, W and Descallar, J and Adams, D and de Souza, P and Harrison, M and Lim, S, Patterns of Presentation and Treatment Outcomes of Non-clear-cell Renal Cell Carcinoma and Sarcomatoid Renal Cell Carcinoma Patients in 2 Tertiary Referral Centers in Sydney, Australia, Clinical Genitourinary Cancer, 17, (3) pp. E565-E569. ISSN 1558-7673 (2019) [Refereed Article]

Copyright Statement

Copyright 2019 Elsevier Inc. All rights reserved.

DOI: doi:10.1016/j.clgc.2019.02.006

Abstract

Background: Noneclear-cell renal cell carcinoma (nccRCC) and renal cell carcinoma with sarcomatoid features (scRCC) are rare, and represent subtypes with less defined treatment strategies. The aim of this study is to describe the patterns of care and outcomes of these patients in 2 tertiary referral centers in South Western Sydney Local Health District over a 10-year period.

Patients and Methods: Patients with RCC seen at South Western Sydney Local Health District from January 1, 2005 to December 31, 2015 were identified from electronic medical records. For each patient, we extracted details regarding demographics, tumor characteristics, treatment, recurrences, and survival, which was analyzed using the Kaplan-Meier method.

Results: Of 178 patients with RCC identified between 2005 and 2015, 23% (n 41) had nccRCC and 8% (n 15) had scRCC. Twenty-five patients in total had de novo metastatic disease or disease recurrence. The median follow-up was 46 and 16 months for nccRCC and scRCC, respectively. The median overall survival for nccRCC with metastatic disease was 34 months (range, 14 months to not reached). Seventy percent of these patients received systemic therapy. By contrast, the median overall survival for scRCC with metastatic disease was 10 months (range, 1.6-89 months). Less than one-half of the patients with scRCC received systemic therapy in our cohort, with only 34% receiving no more than 1 line of treatment.

Conclusions: Our data confirm the rapid and aggressive course of scRCC, highlighting the need for more effective therapeutic strategies in this rare patient population.

Item Details

Item Type:Refereed Article
Keywords:outcomes, recurrence, renal carcinoma, systemic, treatment
Research Division:Medical and Health Sciences
Research Group:Oncology and Carcinogenesis
Research Field:Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cancer and Related Disorders
UTAS Author:Padinharakam, S (Dr Shamsudheen Padinharakam)
ID Code:134513
Year Published:2019
Deposited By:Health Sciences
Deposited On:2019-08-15
Last Modified:2019-09-09
Downloads:0

Repository Staff Only: item control page